ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: cancer

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

  |  

The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…

Late Summer 2023’s Awards, Appointments & Announcements in Rheumatology

  |  

PANLAR Names Eric L. Matteson, MD, a 2023 Master Throughout his career at the Mayo Clinic, Rochester, Minn., Eric L. Matteson, MD, currently professor of rheumatology, emeritus, actively engaged with his rheumatology colleagues in Latin America. He participated in conferences, worked on South American publications and brought rheumatology fellows to the Mayo Clinic for training….

Case Report: Giant Cell Arteritis-Related Stroke

Jessica Meek, MD, Anna Coppinger, DO, & Sejal Khan, DO  |  

Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

What Patients with Lupus Want You to Know

Jacqueline Jansz, MD, with Nadera Sweiss, MD  |  

During a series of interviews with patients who have systemic lupus erythematosus, issues related to medication side effects, supplement use, depression and support groups arose, as well as concerns about race and activities of daily living. The interviews gave me a better understanding of what patients with lupus wish their physicians knew. I am grateful…

Methotrexate Shortage: Why It’s Happening & Potential Solutions

  |  

In recent months, many rheumatologists and rheumatology professionals have noted issues related to obtaining supplies of injectable and oral methotrexate for their patients with rheumatoid arthritis (RA). A conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), methotrexate is available as both oral tablets and as a subcutaneous injection for the treatment of RA and other autoimmune diseases.1…

Case Report: Migratory Polyarthritis as the Presenting Symptom of GPA

Adil Vural, MD, & Kinanah Yaseen, MD  |  

Granulomatosis with polyangiitis (GPA) is a primary, necrotizing granulomatous vasculitis, involving small- to medium-sized arteries, that causes systemic disease. Almost any organ can be affected, but the most affected systems are the upper airways, lungs, kidneys, eyes and peripheral nerves. Migratory polyarthritis is reported in approximately 25% of patients with anti-neutrophil cytoplasmic antibody (ANCA) associated…

Insights from a Neuro-Rheumatology Clinic

Kristin Galetta, MD, Shamik Bhattacharyya, MD, & Simon M. Helfgott, MD  |  

Neuro-rheumatology is a fast-growing field. Better testing and imaging have increased recognition of once-infrequent diagnoses, such as neuro-sarcoidosis and amyloid beta-related angiitis. Concurrently, the rapid expansion of immunotherapy options to treat cancer and their untoward neurological side effects have increased the frequency of referrals to both neurologists and rheumatologists. Identifying and treating neurologic manifestations of…

Cardiovascular Safety with RA Treatments

  |  

Research by Chicre et al. found that Janus kinase inhibitors may significantly increase the risk of major adverse cardiac events and all-cause death in patients with rheumatoid arthritis (RA) when compared with other RA treatments. This study highlights the need for more comparative safety studies.